Stocktoria
Cipla Limited CIPLA.NS
Cipla Limited (CIPLA.NS) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 1.10% (safety: safe). FY2026 revenue was ₹277.1B at a 14.0% net margin.
Price from month-end closes (Yahoo) — for reference, not real-time.
How it ranks in Healthcare · percentile among 46 companies
Percentile vs other Healthcare companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.403 |
| Retained earnings / assets | 0.664 |
| EBIT / assets | 0.114 |
| Equity / liabilities | 4.317 |
FAQ
Is CIPLA.NS financially healthy?
Cipla Limited's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does CIPLA.NS pay a dividend, and is it safe?
Yes. Cipla Limited pays a dividend yielding about 1.10% with a 33.3% payout ratio, rated “safe” for safety.
How profitable is CIPLA.NS?
In FY2026, Cipla Limited had a net margin of 14.0% and a return on equity of 11.3%.
Source: company filings via Yahoo Finance · IN · as of 2026-03-31. Figures in INR; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.